Merck (MRK) said Sunday its immunotherapy drug Keytruda improved by event-free survival by 34% in a phase 3 trial evaluating it as a perioperative treatment for patients with stage III or IVA resected locally advanced head and neck squamous cell carcinoma.
Median event-free survival in the study was 51.8 months to 59.7 months among patients treated with Keytruda in combination with radiotherapy compared 29.6 months to 30.4 months for those treated with radiotherapy alone, the biotech giant said.
Merck said it has a supplemental biologics license application for Keytruda based on the study under priority review with the US Food and Drug Administration with a target action date of June 23.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。